Mark Emalfarb, president and CEO of Dyadic, discusses the company’s fungal-based manufacturing platform, how it can product large volumes of enzymes and other proteins in a fast and cost-effective manner, and the potential this has to change the way biologics are manufactured.

Making Vaccine and Biotherapeutic Production Fast and Affordable

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Business

Investing

Careers

Management & Marketing

Business News

Shopping

Science

Life Sciences

John Lewis, founder and CEO of Aegis Life, discusses the global need to address infectious diseases, the company’s platform technology, and how it is leveraging that to address the barriers to the delivery of vaccines and antibody therapies in developing economies.

How Solving a Problem with Genetic Medicines May Solve Another with Infectious Diseases

Jay Hartenbach, chief operating officer of Diakonos Oncology, discusses the company’s dendritic cell cancer vaccine technology, how it works, and why its lead indication is an aggressive form of brain cancer.

Boosting the Power of Dendritic Cancer Vaccines

James Porter, CEO of Nuvalent, discusses how the company designs drugs that address the challenges of both kinase resistance and selectivity, its pipeline in development, and why it’s critical that its experimental therapy for non-small cell lung cancer can penetrate the brain.

Overcoming Resistance in Cancer with Chemistry

Bobby Azamian, CEO of Tarsus, discusses Lyme disease, the case for the company’s experimental prophylactic drug TP-05, and why you may already have been using a form of the drug to protect a four-legged member of your household.

Teaching an Old Drug a New Trick to Prevent Lyme Disease

Jason Bock, CEO of CMTC, the joint venture between Resilience and MD Anderson Cancer Center, discusses the emerging area of TIL therapies, the significance of the first approved therapy in the class, and how they may address existing limitations of CAR-T therapies.

Making Vaccine and Biotherapeutic Production Fast and Affordable

Download our free app to listen on your phone